Publication
Title
BRAF mutations in non-small cell lung cancer : has finally Janus opened the door?
Author
Abstract
B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warranted to validate these findings. Enrollment of these patients in clinical trials is an interesting strategy to offer a potentially more effective and less toxic targeted therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Language
English
Source (journal)
Critical reviews in oncology, hematology / Chemical Rubber Company [Cleveland, Ohio] - Boca Raton, Fla
Publication
New york : Elsevier science inc, 2016
ISSN
1040-8428
Volume/pages
101(2016), p. 32-39
ISI
000376218000004
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
[E?say:metaLocaldata.cgzprojectinf]
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 05.07.2016
Last edited 19.10.2017
To cite this reference